8-K: Sight Sciences Faces Potential Medicare Coverage Changes for Glaucoma Procedures

Five Medicare Administrative Contractors have proposed draft coverage policies that, if enacted, could impact coverage for certain glaucoma procedures performed with Sight Sciences' OMNI and SION surgical systems.

Summary

• Five Medicare Administrative Contractors (MACs) have published draft local coverage determinations (LCDs) regarding Micro-Invasive Glaucoma Surgery (MIGS).
• These draft LCDs do not propose specific coverage criteria for canaloplasty in combination with trabeculotomy ab interno (associated with Sight Sciences' OMNI system) or goniotomy (associated with the SION system).
• If the draft LCDs become effective in their current form, these procedures would continue to be eligible for Medicare coverage in the states covered by these MACs.
• The states covered by these five MACs accounted for approximately 62% of Sight Sciences' surgical glaucoma revenue in 2023.
• The draft LCDs propose non-coverage policies when an aqueous shunt or stent procedure is combined with a surgical MIGS procedure at the same time of service.
• Each MAC will have a 45-day comment period, followed by a review period, and may finalize the LCDs within 365 days of the original publication date.
• There is a 45-day notice period before a finalized LCD can take effect.
• Sight Sciences plans to engage with the MACs, the Centers for Medicare and Medicaid Services, and clinical societies to support procedures performed with OMNI and SION.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the draft LCDs do not currently propose changes to coverage for Sight Sciences' key procedures, the potential for changes during the review period and the non-coverage policy for combined procedures introduce uncertainty and risk.

Positives

• The draft LCDs do not currently propose to change coverage for canaloplasty with trabeculotomy ab interno (OMNI) or goniotomy (SION) procedures.
• If the draft LCDs are enacted as is, these procedures would continue to be eligible for Medicare coverage in the states covered by the five MACs.

Negatives

• The draft LCDs propose non-coverage for combined aqueous shunt or stent procedures with surgical MIGS procedures at the same time of service.
• There is a risk that the LCDs could be changed during the review period, potentially impacting coverage for Sight Sciences' procedures.

Risks

• The draft LCDs could be revised during the comment and review period, potentially leading to changes in coverage for Sight Sciences' procedures.
• The non-coverage policy for combined procedures could impact the adoption of Sight Sciences' technologies.
• The final LCDs could take up to 365 days to be finalized, creating uncertainty for the company.

Future Outlook

The company plans to actively engage with the MACs, the Centers for Medicare and Medicaid Services, and clinical societies to advocate for continued coverage of procedures performed with OMNI and SION. The final outcome of the LCDs is uncertain and will depend on the feedback received and any revisions made during the review process.

Management Comments

• The Company plans to continue to engage with each MAC, the Centers for Medicare and Medicaid Services, and the clinical societies in continued support of procedures performed with OMNI and SION.

Industry Context

This announcement is significant as it highlights the ongoing challenges and uncertainties surrounding reimbursement for innovative medical technologies in the glaucoma space. Changes in Medicare coverage policies can have a substantial impact on the adoption and commercial success of medical devices like Sight Sciences' OMNI and SION systems. The company's engagement with regulatory bodies and clinical societies is crucial to navigate these challenges.

Comparison to Industry Standards

• The proposed changes in coverage are not unique to Sight Sciences, as other companies in the MIGS space also face similar challenges with Medicare coverage determinations.
• Companies like Glaukos and Ivantis, which also offer MIGS devices, are likely monitoring these developments closely as they could set a precedent for future coverage decisions.
• The 62% revenue exposure to the affected MACs is a significant portion of Sight Sciences' business, highlighting the importance of the outcome of these LCDs.
• The proposed non-coverage of combined procedures is a trend that has been observed in other areas of medical device reimbursement, reflecting a broader effort to control healthcare costs.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the uncertainty surrounding the LCDs.
• Healthcare providers may need to adjust their treatment plans based on the final coverage policies.
• Patients may be affected by changes in coverage for glaucoma procedures.

Next Steps

• Sight Sciences will engage with the MACs, the Centers for Medicare and Medicaid Services, and clinical societies during the 45-day comment period.
• The company will monitor the review process and any potential revisions to the draft LCDs.
• The company will prepare for the possibility of the LCDs being finalized within 365 days of the original publication date.

Key Dates

Keywords

Medicare, Glaucoma, MIGS, Coverage, LCD, OMNI, SION, Canaloplasty, Goniotomy, Healthcare, Reimbursement